Cabozantinib
Reading tools
Cabozantinib (Cabometyx®), which received FDA approval on 25 April 2016, is used in patients previously given treatment to inhibit new blood vessel formation, who have kidney cancer . Cabozantinib exerts its effect through structures called kinases.
By inhibiting the functioning of kinases such as MET, VEGFR 1-2, RET, ROS 1 and KIT, it prevents spread to distant tissues (metastasis), new blood vessel formation and development of resistance to drugs. The most common side effects include diarrhea, fatigue, nausea, reduced appetite, high blood pressure and vomiting.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.